Uncategorized

The diabetes tech company announced a second restructuring after ending its insulin patch-pump program.

The proposal threatens states’ ability to fund state supplemental payment programs for Medicaid, which providers rely on as a boost for revenues.

  El dolor lumbar se erige como una de las principales causas de discapacidad a nivel mundial, afectando a una porción considerable de la población adulta y repercutiendo significativamente en su capacidad para llevar a cabo actividades cotidianas y disfrutar de una buena calid …

Witty’s departure was surprising, though it follows a sharp downturn in the healthcare juggernaut’s financial outlook. He is being replaced by Stephen Hemsley, the chair of UnitedHealth’s board and a previous chief executive.

Witty’s departure was surprising, though it follows a sharp downturn in the healthcare juggernaut’s financial outlook. He is being replaced by Stephen Hemsley, the chair of UnitedHealth’s board and a previous chief executive.

The company plans to start shipping the device in June, starting in California and then expanding nationwide.

It’s another wild twist in the story of Galapagos, a company that has been around for more than 25 years but has yet to get a therapy approved.

Azafaros will use the Series B haul to push lead asset nizubaglustat into late-stage studies for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses later this year.

The Most Favored Nations directive would allow drugmakers to directly sell their products to patients at a lower cost, cutting out what President Donald Trump called “the middlemen.”

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in 2028.